Alazopeptin
Alazopeptin is a non-ribosomal tripeptide azoamino acid antibiotic isolated from various Streptomyces species, with significant anti-tumor, antibacterial and trypanocidal activities. Alazopeptin exhibits cytotoxicity against mouse leukemia cells and S-180 tumor cells, inhibits the growth of Bacillus subtilis, and shows activity against Trypanosoma brucei. Alazopeptin can be widely used in studies related to mouse leukemia, S-180 tumor, human African trypanosomiasis and nagana.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1397-84-8
- Fòrmula: C15H20N6O5
- Peso molecular:364.36
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas Antibiotic
MoreVer todos los productos específicos de isoformas Parasite
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
Trypanosoma |
In Vitro
Alazopeptin exhibits moderate in vitro antitrypanosomal activity and low cytotoxicity against Trypanosoma brucei brucei strain GUTat 3.1 and Trypanosoma brucei rhodesiense strain STIB900[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Trypanosoma brucei brucei strain and Trypanosoma brucei rhodesiense strain STIB900
-
Concentration:IC50
-
Incubation Time:72 h
-
Result:Exhibied Trypanosoma brucei brucei strain GUTat 3.1 (IC50=0.51 μg/mL) and Trypanosoma brucei rhodesiense strain STIB900 (IC50=1.21 μg/mL), with low cytotoxicity against human MRC-5 cells (IC50 >9.10 μg/mL).
In Vivo
Alazopeptin (4.5-36.4 mg/kg; i.v.; daily; 7-10 days) dose-dependently inhibits S-180 solid tumor growth in dd mice[3].
Alazopeptin shows no detectable efficacy against Ehrlich ascites carcinoma in dd mice[3].
Alazopeptin (50 mg/kg; i.p.; daily; 4 consecutive days) does not cure T. b. brucei S427 infection in female ICR mice but increases mean survival day by 1.8-fold relative to controls[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CDF1 mice with Leukemia (~20 g)[3]
-
Dosage:57.3 mg/kg/day; 28.7 mg/kg/day; 14.3 mg/kg/day; 7.2 mg/kg/day; 3.6 mg/kg/day; 1.8 mg/kg/day
-
Administration:i.p.; daily; until death
-
Result:Achieved a mean survival time (MST) T/C of 23.0/8.0 days, corresponding to an average response of 287% at 57.3 mg/kg/day, with all 6 mice surviving.
Achieved an MST T/C of 16.0/8.0 days (average response 200%) at 28.7 mg/kg/day, with all 6 mice surviving.
Achieved an MST T/C of 14.0/8.0 days (average response 175%) at 14.3 mg/kg/day, with all 6 mice surviving.
Achieved an MST T/C of 13.0/8.0 days (average response 163%) at 7.2 mg/kg/day, with all 6 mice surviving.
Achieved an MST T/C of 11.0/8.0 days (average response 138%) at 3.6 mg/kg/day, with all 6 mice surviving.
Achieved an MST T/C of 8.5/8.0 days (average response 107%) at 1.8 mg/kg/day, with all 6 mice surviving.
Showed better efficacy with daily administration than intermittent administration every 2 days.
-
Animal Model:dd mice with Sarcoma[3]
-
Dosage:36.4 mg/kg/day (days 1-10); 18.2 mg/kg/day (days 1-10); 9.1 mg/kg/day (days 1-10); 4.5 mg/kg/day (days 1-10); 36.4 mg/kg/day (days 5-11); 18.2 mg/kg/day (days 5-11); 9.1 mg/kg/day (days 5-11); 4.5 mg/kg/day (days 5-11)
-
Administration:i.v.; daily; 10 days (days 1-10); 7 days (days 5-11)
-
Result:Achieved 100% tumor weight inhibition (tumor weight 0 mg vs control 1401 mg) at 36.4 mg/kg/day (days 1-10), with all 10 mice surviving.
Achieved 99% tumor weight inhibition (tumor weight 8 mg vs control 1401 mg) at 18.2 mg/kg/day (days 1-10), with all 10 mice surviving.
Achieved 89% tumor weight inhibition (tumor weight 158 mg vs control 1401 mg) at 9.1 mg/kg/day (days 1-10), with all 10 mice surviving.
Achieved 21% tumor weight inhibition (tumor weight 1102 mg vs control 1401 mg) at 4.5 mg/kg/day (days 1-10), with all 10 mice surviving.
Achieved 97% tumor weight inhibition (tumor weight 73 mg vs control 2500 mg) at 36.4 mg/kg/day (days 5-11), with all 10 mice surviving.
Achieved 90% tumor weight inhibition (tumor weight 259 mg vs control 2500 mg) at 18.2 mg/kg/day (days 5-11), with all 10 mice surviving.
Achieved 77% tumor weight inhibition (tumor weight 568 mg vs control 2500 mg) at 9.1 mg/kg/day (days 5-11), with all 10 mice surviving.
Achieved 25% tumor weight inhibition (tumor weight 1870 mg vs control 2500 mg) at 4.5 mg/kg/day (days 5-11), with all 10 mice surviving.
Exhibited marked antitumor activity when treatment started 5 days post-transplantation.
Chemical Information
-
No. CAS 1397-84-8
-
Peso molecular 364.36
-
Fòrmula C15H20N6O5
-
SMILES
O=C(O)[C@H](CCC(C=[N+]=[N-])=O)NC([C@H](CCC(C=[N+]=[N-])=O)NCC=C)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Ishiyama A, Otoguro K, Namatame M, et al.. In vitro and in vivo antitrypanosomal activitiy of two microbial metabolites, KS-505a and alazopeptin. The Journal of antibiotics. 2008 Oct;61(10):627-32. [Content Brief]
[2]. Kawai S, Moriga K, Nirdnoy W, et al.. Identification of Two Distinct Stereoselective Lysine 5-Hydroxylases by Genome Mining Based on Alazopeptin Biosynthetic Enzymes. Chemistry (Weinheim an der Bergstrasse, Germany). 2025 Apr 04;31(20):e202404790. [Content Brief]
[4]. Kawai S, Katsuyama Y, Ohnishi Y. The α/β Hydrolase AzpM Catalyzes Dipeptide Synthesis in Alazopeptin Biosynthesis Using Two Molecules of Carrier Protein-Tethered Amino Acid. Chembiochem : a European journal of chemical biology. 2022 Apr 05;23(7):e202100700. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Alazopeptin
- 1397-84-8
- Antibiotic
- Parasite
- Streptacidiphilus griseoplanus
- S-180 tumor cells
- Bacillus subtilis
- Ehrlich ascites carcinoma
- Streptomyces candidus var. azaticus
- Kitasatospora azatica
- human MRC-5 cells
- Trypanosoma brucei brucei
- mouse leukemia L-1210
- Trypanosoma brucei rhodesiense
- Inhibitor
- inhibitor
- inhibit